ArticleInternational journal of radiation biology2014
Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis.
Article in International journal of radiation biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Metallofullerenol ScAdvanced healthcare materials · 2026Article
- Article
- Transcriptomes of Wet Skin Biopsies Predict Outcomes after Ionizing Radiation Exposure with Potential Dosimetric Applications in a Mouse Model.Current issues in molecular biology · 2022Article
- Radiation exposure induces cross-species temporal metabolic changes that are mitigated in mice by amifostine.Scientific reports · 2021Article
- Molecular Hydrogen as a Potential Clinically Applicable Radioprotective Agent.International journal of molecular sciences · 2021Review
- Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.Frontiers in pharmacology · 2021Review
- Protective effects of new aryl sulfone derivatives against radiation-induced hematopoietic injury.Journal of radiation research · 2020Article
- Alterations in Tissue Metabolite Profiles with Amifostine-Prophylaxed Mice Exposed to Gamma Radiation.Metabolites · 2020Article
- Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Article
- Metabolomic studies in tissues of mice treated with amifostine and exposed to gamma-radiation.Scientific reports · 2019Article
- Cyclophosphamide and the taste system: Effects of dose fractionation and amifostine on taste cell renewal.PloS one · 2019Article
- Effects of yak-activated protein on hematopoiesis and related cytokines in radiation-induced injury in mice.Experimental and therapeutic medicine · 2017Article
- THE POTENTIATION OF THE RADIOPROTECTIVE EFFICACY OF TWO MEDICAL COUNTERMEASURES, GAMMA-TOCOTRIENOL AND AMIFOSTINE, BY A COMBINATION PROPHYLACTIC MODALITY.Radiation protection dosimetry · 2016Article
- γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.International journal of molecular sciences · 2016Review
- Use of biomarkers for assessing radiation injury and efficacy of countermeasures.Expert review of molecular diagnostics · 2016Review
- Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.Health physics · 2015Review
- Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice.Journal of radiation research · 2015Article
- Radiation countermeasure agents: an update (2011-2014).Expert opinion on therapeutic patents · 2014Review
- New approaches to radiation protection.Frontiers in oncology · 2014Review
- Protective effects of hydrogen gas inhalation on radiation-induced bone marrow damage in cancer patients: a retrospective observational study.Medical gas researchObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAmifostine is a highly efficacious cytoprotectant when administered in vivo at high doses. However, at elevated doses, drug toxicity manifests for general, non-clinical radioprotective purposes. Various strategies have been developed to avoid toxic side-effects: The simplest is reducing the dose. In terms of protecting hematopoietic tissues, where does this effective, non-toxic minimum dose lie? MATERIAL AND
methodsC3H/HEN mice were administered varying doses of amifostine (25-100 mg/kg) 30 min prior to cobalt-60 irradiation and euthanized between 4-14 days for blood and bone marrow collection and analyses.
resultsUnder steady-state, amifostine had little effect on bipotential and multi-potential marrow progenitors but marginally suppressed a more primitive, lineage negative progenitor subpopulation. In irradiated animals, prophylactic drug doses greater than 50 mg/kg resulted in significant regeneration of bipotential progenitors, moderate regeneration of multipotential progenitors, but no significant and consistent regeneration of more primitive progenitors. The low amifostine dose (25 mg/kg) failed to elicit consistent and positive, radioprotective actions on any of the progenitor subtypes.
conclusionsRadioprotective doses for amifostine appear to lie between 25 and 50 mg/kg. Mature, lineage-restricted progenitors appear to be more responsive to the protective effects of low doses of amifostine than the more primitive, multipotential progenitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.